Failed Post-MI Trial Foils Novartis' Higher ASPIRE-ations For Tekturna
This article was originally published in The Pink Sheet Daily
Executive Summary
ACC panelist: Study was not powered for outcomes, but doubling in death rates is still "very disturbing."
You may also be interested in...
Novartis Takes Cardiovascular Setbacks In Stride After Poor Showing At ACC
Novartis' strategy to expand its cardiovascular and metabolics business in advance of the patent expiry of its blockbuster Diovan included running a lot of clinical trials to add indications and amass outcomes data. But studies designed to expand use also have the potential to disappoint, as was the case for several trials presented at the American College of Cardiology annual meeting
Novartis Takes Cardiovascular Setbacks In Stride After Poor Showing At ACC
Novartis' strategy to expand its cardiovascular and metabolics business in advance of the patent expiry of its blockbuster Diovan included running a lot of clinical trials to add indications and amass outcomes data. But studies designed to expand use also have the potential to disappoint, as was the case for several trials presented at the American College of Cardiology annual meeting
Tekturna Will Track Diovan’s Steady Growth To Blockbuster Status - Novartis
Novartis is hoping sales of its new blood pressure drug Tekturna will climb steadily as morbidity and mortality data amass, eventually leading it to blockbuster status on the same trajectory as top-selling Diovan